Centessa Pharmaceuticals PLC ADR CNTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Are SEM, UNF, CNTA, ASRT Obtaining Fair Deals for their Shareholders?
-
Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?
-
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CLBK, NFBK, AFBI, and CNTA
-
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
-
Are CNTA, KORE, CWAN Obtaining Fair Deals for their Shareholders?
-
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
-
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, CNTA, AFBI, and APLS
-
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?
Trading Information
- Previous Close Price
- $39.75
- Day Range
- $39.69–39.90
- 52-Week Range
- $12.30–40.26
- Bid/Ask
- $39.71 / $40.00
- Shares Outstanding
- 154.73M
- Market Cap
- $6.17B
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 129
- Website
- https://www.centessa.com
Valuation
|
Metric
|
CNTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.61 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CNTA
|
|---|---|
Quick Ratio | 9.27 |
Current Ratio | 9.53 |
Interest Coverage | −22.61 |
Quick Ratio
CNTA
Profitability
|
Metric
|
CNTA
|
|---|---|
Return on Assets (Normalized) | −40.29% |
Return on Equity (Normalized) | −55.06% |
Return on Invested Capital (Normalized) | −43.64% |
Return on Assets
CNTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Qsv | — | |||
| Athersys Inc
ATHXQ
| — | Dyygk | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dhncfjttw | Wwhvjd | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zrzhnwnz | Fcsyys | $64B | |||
| UCB SA
UCBJF
| — | Tfpv | $61B | |||
| UCB SA ADR
UCBJY
| — | Vbqsn | $61B | |||
| argenx SE
ARGNF
| — | Dblf | $56B | |||
| argenx SE ADR
ARGX
| Pvllfhgpq | Vkn | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vpmfyhq | Xbgkdnz | $38B | |||
| CSL Ltd
CMXHF
| — | Bstznh | $36B |
United States